直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in November and December 2023

February 2, 2024

Authored and Edited by Daniel F. Klodowski; Umber Aggarwal; Deena Kablaoui Lanier; Nicholas A. Eitsert; Elliot C. Cook; Aaron L. Parker

In November, the PTAB cancelled 550 (71.34%) instituted claims across 47 IPR and PGR Final Written Decisions, including decisions issued following remand from the Federal Circuit.  After review, 201 (26.07%) instituted claims survived, and patent owners conceded 20 (2.59%) instituted claims through motions to amend or disclaimer.  For comparison, the cumulative average cancellation rate of instituted claims in IPR, CBM, and PGR Final Written Decisions is about 73%.

On a per-case basis, no instituted or substitute claims survived in 26 (55.32%) decisions, all instituted claims survived in 9 (19.15%) decisions, and a mixed outcome occurred in 12 (25.53%) decisions.  A mixed outcome occurs where at least one instituted or substitute claim remains patentable, and at least one is cancelled, in a Final Written Decision. 

In December, the PTAB cancelled 581 (88.03%) instituted claims across 42 IPR and PGR Final Written Decisions. In those decisions, 79 (11.97%) instituted claims survived, and patent owners did not concede any instituted claims through motions to amend or disclaimer. 

On a per-case basis, no instituted or substitute claims survived in 30 (71.43%) decisions, all instituted claims survived in 4 (9.52%) decisions, and a mixed outcome occurred in 8 (19.05%) decisions.  

Through December 31, 2023, the PTAB has cumulatively granted 623 (15.67%) proposed substitute claims in motions to amend while denying 3,354 (84.33%) proposed substitute claims in IPRs. 

The overall cumulative instituted claim survival rate in IPRs, CBMs, and PGRs through December 31, 2023, broken down by technology center, is as follows:

The cumulative number of Final Written Decisions through December 31, 2023, separated by technology center, is as follows:

Related Practices

Appeals, Issues, and Legal Strategy

Federal Circuit and Supreme Court Appeals

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Offices

Reston, VA

Washington, DC

Contacts

Daniel F. Klodowski
Partner
Washington, DC
+1 202 408 4216
Email
Umber Aggarwal
Associate
Reston, VA
+1 571 203 2423
Email
Deena Kablaoui Lanier
Associate
Washington, DC
+1 202 408 4115
Email
Nicholas A. Eitsert
Associate
Washington, DC
+1 202 408 4157
Email
Elliot C. Cook
Partner
Reston, VA
+1 571 203 2738
Email
Aaron L. Parker
Partner
Washington, DC
+1 202 408 4387
Email

Copyright © 2024 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP